[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611629":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":10,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Clear-cell RCC",null,"Participants with clear-cell RCC",[13,14],"Other: Proteomic profiling of urinary EVs","Procedure: Blood sample collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Papillary RCC","Participants with papillary RCC",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Chromophobe RCC","Participants with chromophobe RCC",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Benign Renal Tumor","Participants with benign renal tumors",[13],[28,32],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Proteomic profiling of urinary EVs","EV isolation and mass spectrometry.",[24,20,9,16],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"PROCEDURE","Blood sample collection","Blood samples collected pre- and post-nephrectomy",[20,9,16],[38],{"name":39,"affiliation":5,"role":40},"Fabrice Lucien-Matteoni, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[48],{"facility":49,"status":10,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Mayo Clinic in Rochester","Rochester","Minnesota","55905","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-92.4699,44.02163,{"lat":59,"lon":58},[62,63],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},{"name":39,"role":40,"phone":10,"phoneExt":10,"email":10},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100611629","tumor-derived-extracellular-vesicles-for-noninvasive-molecular-classification-of-kidney-cancer-100611629",false,"NCT07243067","Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer","Inclusion Criteria:\n\n* Urine sample in existing biorepository\n* High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines\n* Scheduled to undergo nephrectomy\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria","ALL",{"count":74,"type":75},300,"ESTIMATED","OBSERVATIONAL","This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.",[79,80,81,82,83],"Renal Cell Carcinoma","Clear-cell Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Kidney Cancer","NOT_YET_RECRUITING","2026-02-24",{"date":87,"type":88},"2026-02-27","ACTUAL",{"date":90,"type":75},"2026-07-15",{"date":92,"type":75},"2027-04-30",{"name":5,"class":6},1]